128 related articles for article (PubMed ID: 33682941)
21. Long Non-Coding RNA (LncRNA)-ATB Promotes Inflammation, Cell Apoptosis and Senescence in Transforming Growth Factor-β1 (TGF-β1) Induced Human Kidney 2 (HK-2) Cells via TGFβ/SMAD2/3 Signaling Pathway.
Sun H; Ke C; Zhang L; Tian C; Zhang Z; Wu S
Med Sci Monit; 2020 May; 26():e922029. PubMed ID: 32447340
[TBL] [Abstract][Full Text] [Related]
22. Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors.
Gatto F; Feelders RA; van Koetsveld PM; Dogan F; Neggers SJCMM; van der Lelij AJ; Amarù J; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2023 Apr; 108(5):e98-e109. PubMed ID: 36413489
[TBL] [Abstract][Full Text] [Related]
23. The proinflammatory LTB4/BLT1 signal axis confers resistance to TGF-β1-induced growth inhibition by targeting Smad3 linker region.
Jeon WK; Choi J; Park SJ; Jo EJ; Lee YK; Lim S; Kim JH; Letterio JJ; Liu F; Kim SJ; Kim BC
Oncotarget; 2015 Dec; 6(39):41650-66. PubMed ID: 26497676
[TBL] [Abstract][Full Text] [Related]
24. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
25. Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism.
Mirzoeva S; Franzen CA; Pelling JC
Mol Carcinog; 2014 Aug; 53(8):598-609. PubMed ID: 23359392
[TBL] [Abstract][Full Text] [Related]
26. Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines.
Dicitore A; Saronni D; Gaudenzi G; Carra S; Cantone MC; Borghi MO; Persani L; Vitale G
J Endocrinol Invest; 2022 Jan; 45(1):29-41. PubMed ID: 34128215
[TBL] [Abstract][Full Text] [Related]
27. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
28. Redox-induced Src kinase and caveolin-1 signaling in TGF-β1-initiated SMAD2/3 activation and PAI-1 expression.
Samarakoon R; Chitnis SS; Higgins SP; Higgins CE; Krepinsky JC; Higgins PJ
PLoS One; 2011; 6(7):e22896. PubMed ID: 21829547
[TBL] [Abstract][Full Text] [Related]
29. Activation of extracellular signal-regulated kinase by TGF-beta1 via TbetaRII and Smad7 dependent mechanisms in human bronchial epithelial BEP2D cells.
Huo YY; Hu YC; He XR; Wang Y; Song BQ; Zhou PK; Zhu MX; Li G; Wu DC
Cell Biol Toxicol; 2007 Mar; 23(2):113-28. PubMed ID: 17096210
[TBL] [Abstract][Full Text] [Related]
30. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
Pisarek H; Pawlikowski M; Kunert-Radek J; Winczyk K
Endokrynol Pol; 2010; 61(2):178-81. PubMed ID: 20464704
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia Suppresses TGF-B1-Induced Cardiac Myocyte Myofibroblast Transformation by Inhibiting Smad2/3 and Rhoa Signaling Pathways.
Yan Z; Shen D; Liao J; Zhang Y; Chen Y; Shi G; Gao F
Cell Physiol Biochem; 2018; 45(1):250-257. PubMed ID: 29357322
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
[TBL] [Abstract][Full Text] [Related]
33. Polarity of response to transforming growth factor-beta1 in proximal tubular epithelial cells is regulated by beta-catenin.
Zhang M; Lee CH; Luo DD; Krupa A; Fraser D; Phillips A
J Biol Chem; 2007 Sep; 282(39):28639-28647. PubMed ID: 17623674
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.
Ben-Shlomo A; Liu NA; Melmed S
Pituitary; 2017 Feb; 20(1):93-99. PubMed ID: 27900635
[TBL] [Abstract][Full Text] [Related]
35. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy.
Yoshihara A; Isozaki O; Hizuka N; Nozoe Y; Harada C; Ono M; Kawamata T; Kubo O; Hori T; Takano K
Endocr J; 2007 Feb; 54(1):133-8. PubMed ID: 17159301
[TBL] [Abstract][Full Text] [Related]
36. [The study of inhibition effect of octreotide on the growth of hepatocellular carcinoma xenografts in situ in nude mice].
Hua YP; Huang JF; Liang LJ; Li SQ; Lai JM; Liang HZ
Zhonghua Wai Ke Za Zhi; 2005 Jun; 43(11):721-5. PubMed ID: 16008961
[TBL] [Abstract][Full Text] [Related]
37. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway.
Heeg MH; Koziolek MJ; Vasko R; Schaefer L; Sharma K; Müller GA; Strutz F
Kidney Int; 2005 Jul; 68(1):96-109. PubMed ID: 15954899
[TBL] [Abstract][Full Text] [Related]
38. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
39. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity.
Barlier A; Pellegrini-Bouiller I; Gunz G; Zamora AJ; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1999 Aug; 84(8):2759-65. PubMed ID: 10443675
[TBL] [Abstract][Full Text] [Related]
40. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
